pharma news today obesity glp-1 agonists and changes in body mass and composition in adults with overweight or with or without type 2 diabetes mellitus: a systematic review and meta-analysis Market Overview: GLP-1 Agonists and

found that in senescent macrophages, mtDNA leakage promoted the cGAS-STING inflammatory pathway, and decreased PINK1/Parkin mediated mitophagy

Sleep quality matters more than most patients expect: Growth hormone secretion, which BPC-157 augments through receptor upregulation, occurs primarily during deep sleep

Studies also examine synaptic-plasticity mechanisms and angiotensin-derived peptide signaling across in-vitro and ex-vivo research systems

CagriSema: A Dual-Target Therapy for Obesity and Type 2 Diabetes Novo Nordisk unveiled the Phase 3 results from the REDEFINE 1 and REDEFINE 2 studies of CagriSema, a fixed-dose combination of cagrilintide (an amylin analog) and semaglutide

Papillary thyroid cancer incidence in the volcanic area of Sicily

Most people see results within 48 weeks: Lower blood sugar Reduced hunger Steady weight loss of 12 pounds per week Making a Safe and Informed Decision GLP-1s arent magicbut theyre science-backed, proven tools for better health